Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Nature Medicine2015Vol. 21(8), pp. 922–926
Citations Over TimeTop 1% of 2015 papers
Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George W. Wright, Chih-Jian Lih, P. Mickey Williams, Arthur L. Shaffer, John F. Gerecitano, Sven de Vos, André Goy, Vaishalee P. Kenkre, Paul M. Barr, Kristie A. Blum, Andrei R. Shustov, Ranjana H. Advani, Nathan Fowler, Julie M. Vose, Rebecca Elstrom, Thomas M. Habermann, Jacqueline C. Barrientos, Jesse McGreivy, Maria Fardis, Betty Chang, Fong Clow, Brian Munneke, Davina Moussa, Darrin M. Beaupre, Louis M. Staudt
Related Papers
- → Targets for Ibrutinib Beyond B Cell Malignancies(2015)127 cited
- → Ibrutinib for B cell malignancies(2014)76 cited
- → Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL(2019)3 cited
- → Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro(2019)1 cited
- → Abstract 3761: HSK26784: An oral PROTAC-BTK degrader for multiple B lymphocyte derived malignancies(2020)